Paradigm Biopharmaceuticals Ltd.ASX: PAR

PPS Shows Significant Pain Benefit in Rest of World Analysis

· Issued by Paradigm Biopharmaceuticals Ltd. via ASX

Filed with ASX · · 8 pages · English

Summary by 6ix AI

The analysis included participants from Australia, Hong Kong, and Moldova, revealing a notable reduction in average daily pain and enhanced physical function. The company is currently assessing the implications of these findings and exploring options for the continued development of its treatment, iPPS, following an interim futility result in the US.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/pps-shows-significant-pain-benefit-in-rest-of-world-analysis-1

Release

1 ASX RELEASE 15 October 2026 Paradigm reports significant pain and function findings in ROW Phase 3 analysis Key Highlights • Further analysis identifies significant pain relief outside the US. Following the overall interim futility result and findings in the US data, Paradigm investigated...

Paradigm Biopharmaceuticals Ltd. on 6ix

Earlier from Paradigm Biopharmaceuticals

All Paradigm Biopharmaceuticals news releases